J Hypertens. 2026 Nov 6. doi: 10.1097/HJH.0000000000004488. Online ahead of print.
ABSTRACT
BACKGROUND: Current recommendations support measuring plasma renin and aldosterone in all adults with hypertension to detect primary aldosteronism (PA). However, clinical guidelines do not address individuals with low renin (commonly defined as a direct renin concentration <10 mU/l or plasma renin activity <1 ng/ml/h) who do not meet diagnostic criteria for PA and have normal or low aldosterone concentration, a normal aldosterone-to-renin ratio, and/or adequate suppression of aldosterone following salt loading or captopril challenge. This systematic review aimed to estimate the global prevalence of low-renin hypertension, as emerging evidence suggests this group may benefit from treatment distinct from standard antihypertensive therapy.
METHODS: The protocol was registered with PROSPERO (CRD42023467251). MEDLINE, Embase, and Cochrane databases were searched for studies reporting renin measurements in hypertension. Two reviewers independently screened studies and extracted data, with disagreements resolved by consensus. Study quality was assessed using the Joanna Briggs Institute tool. Pooled prevalence estimates and heterogeneity were calculated using random-intercept logistic regression and I2 statistics.
RESULTS: Of 2745 records identified (1968-2024), 56 studies involving 13 210 participants met inclusion criteria. The pooled prevalence of low-renin hypertension was 32% (95% CI 28-35%; I2 = 94%). Prevalence was higher in studies with >70% Black participants (47% vs. 30%, P = 0.034). In studies with confirmatory testing to exclude PA, the pooled prevalence was 27% (95% CI 25-29%; I2 = 0%).
CONCLUSION: Low-renin hypertension affects a substantial proportion of individuals with hypertension, particularly among Black populations. Further research is necessary to guide optimal management.
PMID:42992398 | DOI:10.1097/HJH.0000000000004488

